JP2019515031A5 - - Google Patents

Download PDF

Info

Publication number
JP2019515031A5
JP2019515031A5 JP2019506612A JP2019506612A JP2019515031A5 JP 2019515031 A5 JP2019515031 A5 JP 2019515031A5 JP 2019506612 A JP2019506612 A JP 2019506612A JP 2019506612 A JP2019506612 A JP 2019506612A JP 2019515031 A5 JP2019515031 A5 JP 2019515031A5
Authority
JP
Japan
Prior art keywords
plant
cannabis
composition according
derived composition
derived
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019506612A
Other languages
English (en)
Japanese (ja)
Other versions
JP6983868B2 (ja
JP2019515031A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/028953 external-priority patent/WO2017185038A1/en
Publication of JP2019515031A publication Critical patent/JP2019515031A/ja
Publication of JP2019515031A5 publication Critical patent/JP2019515031A5/ja
Priority to JP2021189167A priority Critical patent/JP7284241B2/ja
Application granted granted Critical
Publication of JP6983868B2 publication Critical patent/JP6983868B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019506612A 2016-04-22 2017-04-21 即効性の植物由来医薬化合物及び栄養補給剤 Active JP6983868B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021189167A JP7284241B2 (ja) 2016-04-22 2021-11-22 即効性の植物由来医薬化合物及び栄養補給剤

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662326490P 2016-04-22 2016-04-22
US62/326,490 2016-04-22
US201662429544P 2016-12-02 2016-12-02
US62/429,544 2016-12-02
PCT/US2017/028953 WO2017185038A1 (en) 2016-04-22 2017-04-21 Fast-acting plant-based medicinal compounds and nutritional supplements

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021189167A Division JP7284241B2 (ja) 2016-04-22 2021-11-22 即効性の植物由来医薬化合物及び栄養補給剤

Publications (3)

Publication Number Publication Date
JP2019515031A JP2019515031A (ja) 2019-06-06
JP2019515031A5 true JP2019515031A5 (https=) 2020-05-28
JP6983868B2 JP6983868B2 (ja) 2021-12-17

Family

ID=60117058

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2019506612A Active JP6983868B2 (ja) 2016-04-22 2017-04-21 即効性の植物由来医薬化合物及び栄養補給剤
JP2021189167A Active JP7284241B2 (ja) 2016-04-22 2021-11-22 即効性の植物由来医薬化合物及び栄養補給剤
JP2023081364A Active JP7671079B2 (ja) 2016-04-22 2023-05-17 即効性の植物由来医薬化合物及び栄養補給剤
JP2025065534A Pending JP2025108565A (ja) 2016-04-22 2025-04-11 即効性の植物由来医薬化合物及び栄養補給剤

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2021189167A Active JP7284241B2 (ja) 2016-04-22 2021-11-22 即効性の植物由来医薬化合物及び栄養補給剤
JP2023081364A Active JP7671079B2 (ja) 2016-04-22 2023-05-17 即効性の植物由来医薬化合物及び栄養補給剤
JP2025065534A Pending JP2025108565A (ja) 2016-04-22 2025-04-11 即効性の植物由来医薬化合物及び栄養補給剤

Country Status (13)

Country Link
US (5) US10588974B2 (https=)
EP (2) EP3928776B1 (https=)
JP (4) JP6983868B2 (https=)
KR (1) KR102393596B1 (https=)
CN (1) CN109069475B (https=)
AU (3) AU2017252575B2 (https=)
BR (1) BR112018071518A2 (https=)
CA (1) CA3021660A1 (https=)
CL (1) CL2018002997A1 (https=)
CO (1) CO2018011299A2 (https=)
IL (2) IL262505B (https=)
MX (2) MX382853B (https=)
WO (1) WO2017185038A1 (https=)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12137716B2 (en) 2015-04-16 2024-11-12 Michael Hudnall Methods of liver disease treatment
BR112018071518A2 (pt) * 2016-04-22 2019-02-19 Receptor Life Sciences, Inc. compostos medicinais à base de planta de ação rápida e suplementos nutricionais
EA201892396A1 (ru) * 2016-12-02 2019-04-30 Ресептор Лайф Сайенсиз, Инк. Быстродействующие растительные лекарственные соединения и биологически активные добавки
US10239808B1 (en) 2016-12-07 2019-03-26 Canopy Holdings, LLC Cannabis extracts
US20190336472A1 (en) * 2017-01-03 2019-11-07 Receptor Holdings, Inc. Medicinal compounds and nutritional supplements
BR112019019776A2 (pt) * 2017-03-23 2020-04-22 Receptor Holdings, Inc. entrega rápida e controlada de composições com efeitos entourage restaurados
CA3089994A1 (en) 2018-01-31 2019-08-08 Canopy Holdings, LLC Hemp powder
US20190321330A1 (en) * 2018-04-18 2019-10-24 Canopy Growth Corporation Cannabis placebo compositions, delivery vehicles and a method for colour matching/neutralization of cannabis products
WO2020077153A1 (en) 2018-10-10 2020-04-16 Canopy Holdings, LLC Synthesis of cannabigerol
EP3883595A4 (en) 2018-11-19 2022-12-14 Receptor Holdings, Inc. N-ACYLATED FATTY AMINO ACIDS TO REDUCE ABSORPTION VARIABILITY IN CANNABINOID-BASED COMPOSITIONS
WO2020146478A1 (en) * 2019-01-08 2020-07-16 Replennabis LLC Cannabinoid formulations for treating alcohol hangover
EP3920904A4 (en) * 2019-02-08 2022-11-09 Schedule 1 Therapeutics, Inc. COMPOSITIONS CONTAINING CANNABINOIDS AND METHODS OF USE THEREOF
US11622956B1 (en) 2019-06-26 2023-04-11 RCR BioPharma Compound and method for treating diseases and disorders
EP3994114A4 (en) * 2019-07-04 2023-08-16 Canopy Growth Corporation CANNABINOID DERIVATIVES
US12252503B2 (en) 2019-07-12 2025-03-18 Canopy Growth Corporation Cannabinoid derivatives
EP3946262B1 (en) 2019-08-30 2024-07-31 Evie Sa Loaded granules, their process of production and their uses
AU2020358869A1 (en) 2019-10-03 2022-04-14 Pike Therapeutics Usa, Inc. Transdermal delivery of dronabinol
US12409131B2 (en) 2019-10-03 2025-09-09 Pike Therapeutics Usa, Inc. Transdermal delivery of dronabinol
EP4041209A4 (en) 2019-10-11 2024-01-24 Pike Therapeutics, Inc. TRANSDERMAL COMPOSITIONS COMPRISING CANNABIDIOL (CBD) FOR USE IN THE TREATMENT OF EPILEPTIC DISORDERS
US12016829B2 (en) 2019-10-11 2024-06-25 Pike Therapeutics Inc. Pharmaceutical composition and method for treating seizure disorders
US12121617B2 (en) 2019-10-14 2024-10-22 Pike Therapeutics Inc. Transdermal delivery of cannabidiol
US12268699B2 (en) 2019-10-14 2025-04-08 Pike Therapeutics Inc. Transdermal delivery of tetrahydrocannabinol
CA3155181A1 (en) 2019-10-14 2021-04-22 Pike Therapeutics, Inc., 1219014 B.C. Ltd. Transdermal delivery of cannabidiol
CN111517980B (zh) * 2020-05-14 2021-02-09 台州浦凯医药科技有限公司 N-[8-(2-羟基苯甲酰基)氨基]辛酸一钾晶型化合物、制备方法及用途
CN113735734B (zh) * 2020-05-29 2023-12-08 杭州先为达生物科技股份有限公司 N-[8-(2-羟基苯甲酰基)氨基]辛酸钾晶体多晶型物及其制备方法和用途
EP4159712B1 (en) * 2020-05-29 2025-03-19 Sciwind Biosciences Co., Ltd. N-[8-(2-hydroxybenzoyl)amino]potassium octanoate crystal polymorph, and preparation method therefor and use thereof
US11938152B2 (en) 2020-08-06 2024-03-26 Kedar N Prasad High-dose antioxidants in cancer treatment
US12029718B2 (en) 2021-11-09 2024-07-09 Cct Sciences, Llc Process for production of essentially pure delta-9-tetrahydrocannabinol
WO2023287891A1 (en) * 2021-07-13 2023-01-19 Demetrix, Inc. Compositions and methods using cannabinoid compounds for regulating gastric acid secretion to treat gastroesophageal reflux disease and related conditions
WO2023091173A1 (en) * 2021-11-16 2023-05-25 Michael Hudnall Methods of liver disease treatment
CN114539091B (zh) * 2022-03-11 2024-11-05 佛山奕安赛医药科技有限公司 异棕榈酰氨基酸类化合物及其制备方法和应用
CN116474049A (zh) * 2023-03-17 2023-07-25 深圳福图仁泰生物科技有限公司 一种兼具抗抑郁和促睡眠功效的植物天然水溶性复合物及其制备方法和应用
WO2025054536A1 (en) * 2023-09-07 2025-03-13 The Regents Of The University Of California Cannabinoid delivery

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2385365A (en) 1943-02-17 1945-09-25 Wisconsin Alumni Res Found Salicylic acid compounds for safer therapeutic use
US3939259A (en) 1974-05-24 1976-02-17 Anthony Pescetti Coating composition and therapeutic preparation incorporating same
DE2537232B2 (de) 1974-08-22 1976-07-01 Spritz- und formmasse
US4374082A (en) 1981-08-18 1983-02-15 Richard Hochschild Method for making a pharmaceutical and/or nutritional dosage form
ES2039226T3 (es) 1986-12-30 1993-09-16 American Cyanamid Company Procedimiento para preparar composiciones que contienen policarbofil.
US4758597A (en) 1987-05-15 1988-07-19 University Patents, Inc. Carenadiol and derivatives
US4902513A (en) 1987-07-31 1990-02-20 Jean Carvais Oral sustained release medicament
US5965162A (en) 1993-09-10 1999-10-12 Fuisz Technologies Ltd. Process for forming chewable quickly dispersing multi-vitamin preparation and product therefrom
US5650386A (en) 1995-03-31 1997-07-22 Emisphere Technologies, Inc. Compositions for oral delivery of active agents
US5866536A (en) 1995-03-31 1999-02-02 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
CN1151836C (zh) * 1995-03-31 2004-06-02 艾米斯菲尔技术有限公司 用作传送活性剂的化合物和组合物
EP1049474A4 (en) 1998-11-24 2004-12-29 Univ Connecticut CANNABIMIMETIC LIPID AMIDES FOR USE AS MEDICINES
JP2000256323A (ja) 1999-01-08 2000-09-19 Japan Tobacco Inc ２−オキソキノリン化合物及びその医薬用途
ES2235854T3 (es) 1999-04-05 2005-07-16 Emisphere Technologies, Inc. Sales disodicas, monohidratos y solvatos etanolicos para aportar agentes activos.
US6495177B1 (en) 1999-08-13 2002-12-17 Warner Chilcott Laboratories Ireland Limited Orally dissolvable nutritional supplement
WO2001019901A2 (en) 1999-09-14 2001-03-22 Smithkline Beecham Corporation Process for making aqueous coated beadlets
GB0007419D0 (en) 2000-03-27 2000-05-17 Smithkline Beecham Gmbh Composition
EP1231273A1 (en) 2001-02-12 2002-08-14 Plant Research International B.V. Terpene synthase/cyclase and olefin synthase and uses thereof
GB2377633A (en) 2001-05-11 2003-01-22 Gw Pharmaceuticals Ltd Pharmaceutical compositions comprising the cannabinoids THC and CBD
DK1361864T3 (en) 2001-02-14 2014-03-03 Gw Pharma Ltd FLYLDENDE SPRAY FORMULATIONS FOR buccal administration of cannabinoids
JP5026655B2 (ja) 2001-04-18 2012-09-12 プロメティック、バイオサイエンシーズ、インコーポレーテッド 好中球の生存及び活性化因子としての中鎖脂肪酸、グリセリド及び類似体
IL143318A0 (en) 2001-05-23 2002-04-21 Herbal Synthesis Corp Herbal compositions for the treatment of mucosal lesions
CA2466863A1 (en) * 2001-11-29 2003-06-05 Emisphere Technologies, Inc. Oral pharmaceutical compositions comprising cromolyn sodium and an acylated amino acid
EP1492511B3 (fr) 2002-04-09 2012-05-02 Flamel Technologies Formulation pharmaceutique orale sous forme de suspension aqueuse de microcapsules permettant la liberation modifiee de principe(s) actif(s)
UY27939A1 (es) 2002-08-21 2004-03-31 Glaxo Group Ltd Compuestos
GB0222077D0 (en) 2002-09-23 2002-10-30 Gw Pharma Ltd Methods of preparing cannabinoids from plant material
CA2507815A1 (en) 2002-12-04 2004-06-17 Pharmos Corporation High enantiomeric purity dexanabinol for pharmaceutical compositions
AU2003301121A1 (en) 2002-12-18 2004-07-14 Pain Therapeutics, Inc. Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats
AU2004296877A1 (en) 2003-12-09 2005-06-23 Incyte Corporation Dosing methods for ss-D-2',3'-dideoxy-2',3'-didehydro-5-fluorocytidine antiviral therapy
US20050191349A1 (en) 2003-12-31 2005-09-01 Garth Boehm Galantamine formulations
IL162636A0 (en) 2004-06-20 2005-11-20 Yissum Res Dev Co Resorcinol derivatives and their use for lowering blood pressure
CN101076324A (zh) 2004-10-22 2007-11-21 法玛氏公司 口服有效的大麻素类似物
TWI360539B (en) 2004-10-28 2012-03-21 Shionogi & Co 3-carbamoyl-2-pyridone derivatives
GB0507167D0 (en) 2005-04-08 2005-05-18 Glaxosmithkline Consumer Healt Composition
TWI366460B (en) 2005-06-16 2012-06-21 Euro Celtique Sa Cannabinoid active pharmaceutical ingredient for improved dosage forms
EP1893753B1 (en) 2005-06-17 2015-12-23 Firmenich Sa Novel sesquiterpene synthases and methods of their use
US9125833B2 (en) 2005-11-02 2015-09-08 Relmada Therapeutics, Inc. Multimodal abuse resistant and extended release opioid formulations
US20070104741A1 (en) * 2005-11-07 2007-05-10 Murty Pharmaceuticals, Inc. Delivery of tetrahydrocannabinol
US9265724B2 (en) 2005-11-07 2016-02-23 Ram B. Murty Oral dosage form of tetrahydrocannabinol and a method of avoiding and/or suppressing hepatic first pass metabolism via targeted chylomicron/lipoprotein delivery
UY30090A1 (es) 2006-01-16 2007-08-31 Syngenta Participations Ag Insecticidas novedosos
US20070254911A1 (en) 2006-03-27 2007-11-01 Mingde Xia Tetrahydro-Pyrazolo[3,4-c]Pyridine Cannabinoid Modulators
WO2008024408A2 (en) 2006-08-22 2008-02-28 Theraquest Biosciences, Inc. Pharmaceutical formulations of cannabinoids for application to the skin and method of use
CA2662123C (en) 2006-08-30 2015-12-01 Jagotec Ag Controlled release oral dosage formulations comprising a core and one or more barrier layers
GB0624340D0 (en) 2006-12-06 2007-01-17 Nature Therapeutics Ltd Antimicrobial composition
EP2139333A4 (en) 2007-03-28 2010-11-10 Merck Sharp & Dohme SUBSTITUTED PYRID- [3,2-E] - [1,2,4] -TRIAZOL- [4,3-C] -PYRIMIDINE DERIVATIVES AS CANNABINOID-1 RECEPTOR MODULATORS
PL2215047T3 (pl) 2007-11-02 2014-05-30 Emisphere Tech Inc Sposób leczenia niedoborów witaminy b12
US20090155392A1 (en) 2007-12-17 2009-06-18 Bret David Nelson Methods and Systems for Sublingual Guarana Administration
WO2009100245A1 (en) 2008-02-05 2009-08-13 Emisphere Technologies Inc. Low dose hmg-coa reductase inhibitor with reduced side effects
US20110137040A1 (en) 2008-08-01 2011-06-09 Lange Josephus H M Synthesis of 3,4-diaryl-4,5-dihydro-(h)-pyrazole-1-carboxamidine derivatives
JP5740689B2 (ja) 2008-08-18 2015-06-24 エンテラ バイオ エルティーディー． タンパク質の経口投与用の方法および組成物
CN101439074B (zh) 2008-12-11 2012-06-06 深圳海王药业有限公司 苍术总萜醇提取物及其制备方法和用途
CA2760460C (en) 2009-04-28 2019-04-02 Alltranz Inc. Transdermal formulations of cannabidiol comprising a penetration enhancer and methods of using the same
CA2785056A1 (en) 2009-12-22 2011-07-21 Pondera Biotechnologies, LLC Methods and compositions for treating distress dysfunction and enhancing safety and efficacy of specific medications
SG190024A1 (en) 2010-11-25 2013-06-28 Aop Orphan Pharmaceuticals Ag Fast disintegrating compositions comprising nabilone and randomly methylated beta cyclodextrin
US20130224300A1 (en) 2011-08-26 2013-08-29 Edward T. Maggio Compositions and methods thereof for oral administration of drugs
ES2806034T3 (es) 2011-09-29 2021-02-16 Thc Pharm Gmbh The Health Concept Acidos carboxílicos de cannabinoide, sales de ácidos carboxílicos de cannabinoide, su preparación y aplicaciones
EP2601947A1 (en) 2011-12-05 2013-06-12 Abo Bakr Mohammed Ali Al-Mehdar Fixed-dose combination for treatment of helicobacter pylori associated diseases
US20150050373A1 (en) 2012-03-13 2015-02-19 Piramal Enterprises Limited Herbal composition for the treatment of metabolic disorders
WO2013165251A1 (en) 2012-05-03 2013-11-07 Echo Pharmaceuticals B.V. Cannabis plant isolate comprising /\9-tetrahydrocannabinol and a method for preparing such an isolate
EP2666461B1 (en) 2012-05-23 2015-07-01 Tergum S.L. Terpene extract for the treatment of hair loss
PL2897620T3 (pl) 2012-09-21 2020-11-02 Intensity Therapeutics, Inc Sposób leczenia nowotworu złośliwego
WO2014060472A1 (en) 2012-10-17 2014-04-24 Novo Nordisk A/S Fatty acid acylated amino acids for oral peptide delivery
US10639439B2 (en) * 2013-01-30 2020-05-05 Midwest Pharmaceuticals, Llc Smokeless THC and administration method thereof
CA3012383C (en) 2013-02-28 2021-03-02 Teewinot Technologies Limited Biosynthesis of cannabinoids
EP2968259B1 (en) 2013-03-14 2022-09-14 SC Laboratories Inc. Bioactive concentrates and uses thereof
MX2015011896A (es) 2013-03-15 2016-07-19 Korea United Pharm Inc Formulacion de liberacion sostenida de mosapride que proporciona efectos farmacologicos y clinicos con administracion una vez al dia.
JP6041823B2 (ja) 2013-03-16 2016-12-14 ファイザー・インク トファシチニブの経口持続放出剤形
US9326967B2 (en) * 2013-08-22 2016-05-03 Stephen C. Perry Vaporizable cannabinoid compositions
US9532593B2 (en) * 2013-12-26 2017-01-03 John Turner Herbal smoking blend
WO2015118549A1 (en) 2014-02-10 2015-08-13 F&C Licorice Ltd. Encapsulated biologically active agents
CA2845443A1 (en) 2014-03-04 2015-09-04 Pharmascience Inc. Orally disintegrating tablet of nabilone and method of manufacturing
GB2527599A (en) 2014-06-27 2015-12-30 Gw Pharma Ltd Use of 7-OH-Cannabidiol (7-OH-CBD) and/or 7-OH-Cannabidivarin (7-OH-CBDV) in the treatment of epilepsy
WO2016022936A1 (en) * 2014-08-07 2016-02-11 Murty Pharmaceuticals, Inc. An improved oral gastrointestinal dosage form delivery system of cannabinoids and/or standardized marijuana extracts
US9375417B2 (en) 2014-12-04 2016-06-28 Mary's Medicinals LLC Transdermal cannabinoid formulations
AU2016225026A1 (en) 2015-02-27 2017-09-07 Canopy Growth Corporation Compositions comprising combinations of purified cannabinoids, with at least one flavonoid, terpene, or mineral
WO2016205923A1 (en) 2015-06-25 2016-12-29 Compressed Perforated Puck Technologies Inc. Ingestible plant source pill and method
BR112018071518A2 (pt) 2016-04-22 2019-02-19 Receptor Life Sciences, Inc. compostos medicinais à base de planta de ação rápida e suplementos nutricionais
EA201892396A1 (ru) 2016-12-02 2019-04-30 Ресептор Лайф Сайенсиз, Инк. Быстродействующие растительные лекарственные соединения и биологически активные добавки
US20190336472A1 (en) 2017-01-03 2019-11-07 Receptor Holdings, Inc. Medicinal compounds and nutritional supplements
AU2018233582B2 (en) 2017-03-16 2022-04-07 CannTab Therapeutics, Limited Modified release multi-layer tablet cannabinoid formulations
BR112019019776A2 (pt) 2017-03-23 2020-04-22 Receptor Holdings, Inc. entrega rápida e controlada de composições com efeitos entourage restaurados
JP2020536858A (ja) 2017-10-05 2020-12-17 レセプター・ホールディングス・インコーポレイテッド 改善されたバイオアベイラビリティーを有するハーブ組成物
CA3078549A1 (en) 2017-10-05 2019-04-11 Receptor Holdings, Inc. Rapid onset and extended action plant-based and synthetic cannabinoid formulations

Similar Documents

Publication Publication Date Title
JP2019515031A5 (https=)
JP2020500876A5 (https=)
AU2020201457B2 (en) Compositions and methods for managing or improving bone disorders, cartilage disorders, or both
Borges et al. Anti-inflammatory activity of nanoemulsions of essential oil from Rosmarinus officinalis L.: in vitro and in zebrafish studies
Gargouri et al. Cytoprotective and antioxidant effects of the edible halophyte Sarcocornia perennis L.(swampfire) against lead-induced toxicity in renal cells
Mikail Phytochemical screening, elemental analysis and acute toxicity of aqueous extract of Allium sativum L. bulbs in experimental rabbits
JP2023071697A5 (https=)
JP2010524912A5 (https=)
Mssillou et al. LC-TOFMS analysis, in vitro and in silico antioxidant activity on NADPH oxidase, and toxicity assessment of an extract mixture based on Marrubium vulgare L. and Dittrichia viscosa L.
EP4284351A1 (en) Composition for the treatment of painful and/or inflammatory states
Onyesife et al. Nephroprotective effects of Piper nigrum extracts against monosodium glutamate-induced renal toxicity in rats
Palmeira-de-Oliveira et al. Are plant extracts a potential therapeutic approach for genital infections?
Shokry et al. Phytochemical contents, biological activities and therapeutic applications of hedera helix (ivy leaf) extracts: a review
Raus de Baviera et al. Cistus albidus L.—review of a traditional mediterranean medicinal plant with pharmacological potential
Al-Baroudi et al. Hepatoprotective effect of chamomile capitula extract against 2, 4-dichlorophenoxyacetic acid-induced hepatotoxicity in rats
RU2007132962A (ru) Применение гидроксистильбенсодержащих активных веществ для профилактики и/или лечения остеопороза
Takate et al. Hepato-protective activity of the ethyl acetate extract of launaea intybacea (jacq) beauv in paracetamol induced hepato-toxicity in albino rats. group
Gomaa Darwish et al. In vitro antileishmanial activity of methanolic extracts for some selected medicinal plants
WO2021194436A1 (en) The natural antiviral and anti-inflammatory compound consist of bioflavonoids which extracted from papaver rhoeas red petals
Gyawali et al. Hepatoprotective properties of selected plants against paracetamol-induced hepatotoxicity in mice
Kumarl et al. Hypericum perforatUln: Nature's mood stabilizer
Denes et al. Phytochemical investigation and antioxidant potential of Ononis Arvensis L
Manasathien EFFECTS OF MANGOSTEEN HULL EXTRACTS ON BIOEFFICACY AND ANTIPROLIFERATION OF HUMAN BREAST AND PROSTATE CARCINOMA CELL LINES.
Khaliq et al. Medicinal plants against COVID-19
Murugananthan et al. Medicinal plants with potent antioxidant constituents